Published on May 14, 2013
Supporting research at
http://www.skizit.biz/2013/07/21/ecdy...
For more information on gene therapy and human hair in Morgellons, please see
http://www.youtube.com/watch?v=x9ab-i...
If you have any questions, please write me at skizit@hushmail.com.
Please use the donate button on my channel or website.
Your donation helps purchase microscopes, cameras, books, articles, research computer and software. There are people who cannot afford the various treatments that could make their lives more bearable with this disease. There are ways you can help. Thanks for supporting this research.
What is a possible treatment for Morgellons insects, bacteria and fungi?
See http://www.nap.edu/openbook.php?recor...
Medicinal Uses for Neem Tree Oil (take internally and on skin)
Morgellons patents:
US 6245531 Polynucleotides Encoding Insect Ecdysone Receptor
http://www.patentlens.net/imageserver...
US 5514578A Polynucleotides Encoding Insect Steroid Hormone Receptor Polypeptides and Cells Transformed With Same
http://www.patentlens.net/patentlens/...
Inventors:
David Hogness
650-723-6166
tran@cmgm.stanford.edu
Michael Koelle
203-432-5662
Michael.koelle@yale.edu
William Seagraves
203-432-4537
William.seagraves@yale.edu
----------------------------------------
Who markets this Inducible Expression System?
SPRING HOUSE, Pa.--(BW HealthWire)--May 7, 2002
Agreement grants Invitrogen nonexclusive, worldwide rights
to manufacture and sell Ecdysone-Inducible Expression research kits
RHeoGene today announced it has negotiated an agreement to grant Invitrogen (Carlsbad, CA) a nonexclusive, worldwide sublicense for sales of Invitrogen's Ecdysone-Inducible Expression System and related products for research purposes only. RHeoGene holds an exclusive license to Stanford University patents U.S. 5,514,578, 6,245,531 and EP Patent 0517805 that cover sales and use of certain ecdysone-based products.
Invitrogen has been manufacturing and selling its Ecdysone- Inducible Expression System under a separate license since 1996. Under its license from RHeoGene, Invitrogen will continue to provide Ecdysone-Inducible Expression System products to academic, government, industrial, and clinical institutions for research purposes. Customers wishing to use ecdysone receptor-based gene expression systems for commercial purposes should contact RHeoGene for a commercial license.
"This licensing agreement is the first external validation of the importance of RHeoGene's exclusive license to the intellectual property encompassed by these Stanford patents after broader claims to U.S. 5,514,578 were granted," said Tom Tillett, RHeoGene Executive Vice President for Operations.
The Stanford patents are directed to genes that encode insect-based ecdysone receptors from a broad range of insect species and methods for regulating gene expression in host cells. The patent coverage includes ecdysone receptor (EcR) genes originating from Drosophila, the basis of Invitrogen's Ecdysone-Inducible Expression System. The patents are based on the pioneering research of Dr. David Hogness, Emeritus Munzer Professor of Developmental Biology and Biochemistry at Stanford University. RHeoGene's exclusive license to these patents encompasses all uses outside of plants, including cell-based assays, genomics, proteomics, gene therapy, cell culture/fermentation, transgenic animals, and biosensors.
Financial terms were not disclosed.
RHeoGene is the source for advanced applications, products, and technologies that manage gene expression. Seamlessly integrating biology and chemistry applications that deliver precise management of gene regulation, RHeoGene focuses on delivering customized inducible gene expression technology systems to advance proteomics, drug discovery, biotherapeutics production, and human gene therapy. RHeoGene's operations are located in Spring House, Pa., and Charlottesville, Va. For more information, visit www.rheogene.com.
SOURCE: RHeoGene
http://www.skizit.biz/2013/07/21/ecdy...
For more information on gene therapy and human hair in Morgellons, please see
http://www.youtube.com/watch?v=x9ab-i...
If you have any questions, please write me at skizit@hushmail.com.
Please use the donate button on my channel or website.
Your donation helps purchase microscopes, cameras, books, articles, research computer and software. There are people who cannot afford the various treatments that could make their lives more bearable with this disease. There are ways you can help. Thanks for supporting this research.
What is a possible treatment for Morgellons insects, bacteria and fungi?
See http://www.nap.edu/openbook.php?recor...
Medicinal Uses for Neem Tree Oil (take internally and on skin)
Morgellons patents:
US 6245531 Polynucleotides Encoding Insect Ecdysone Receptor
http://www.patentlens.net/imageserver...
US 5514578A Polynucleotides Encoding Insect Steroid Hormone Receptor Polypeptides and Cells Transformed With Same
http://www.patentlens.net/patentlens/...
Inventors:
David Hogness
650-723-6166
tran@cmgm.stanford.edu
Michael Koelle
203-432-5662
Michael.koelle@yale.edu
William Seagraves
203-432-4537
William.seagraves@yale.edu
----------------------------------------
Who markets this Inducible Expression System?
SPRING HOUSE, Pa.--(BW HealthWire)--May 7, 2002
Agreement grants Invitrogen nonexclusive, worldwide rights
to manufacture and sell Ecdysone-Inducible Expression research kits
RHeoGene today announced it has negotiated an agreement to grant Invitrogen (Carlsbad, CA) a nonexclusive, worldwide sublicense for sales of Invitrogen's Ecdysone-Inducible Expression System and related products for research purposes only. RHeoGene holds an exclusive license to Stanford University patents U.S. 5,514,578, 6,245,531 and EP Patent 0517805 that cover sales and use of certain ecdysone-based products.
Invitrogen has been manufacturing and selling its Ecdysone- Inducible Expression System under a separate license since 1996. Under its license from RHeoGene, Invitrogen will continue to provide Ecdysone-Inducible Expression System products to academic, government, industrial, and clinical institutions for research purposes. Customers wishing to use ecdysone receptor-based gene expression systems for commercial purposes should contact RHeoGene for a commercial license.
"This licensing agreement is the first external validation of the importance of RHeoGene's exclusive license to the intellectual property encompassed by these Stanford patents after broader claims to U.S. 5,514,578 were granted," said Tom Tillett, RHeoGene Executive Vice President for Operations.
The Stanford patents are directed to genes that encode insect-based ecdysone receptors from a broad range of insect species and methods for regulating gene expression in host cells. The patent coverage includes ecdysone receptor (EcR) genes originating from Drosophila, the basis of Invitrogen's Ecdysone-Inducible Expression System. The patents are based on the pioneering research of Dr. David Hogness, Emeritus Munzer Professor of Developmental Biology and Biochemistry at Stanford University. RHeoGene's exclusive license to these patents encompasses all uses outside of plants, including cell-based assays, genomics, proteomics, gene therapy, cell culture/fermentation, transgenic animals, and biosensors.
Financial terms were not disclosed.
RHeoGene is the source for advanced applications, products, and technologies that manage gene expression. Seamlessly integrating biology and chemistry applications that deliver precise management of gene regulation, RHeoGene focuses on delivering customized inducible gene expression technology systems to advance proteomics, drug discovery, biotherapeutics production, and human gene therapy. RHeoGene's operations are located in Spring House, Pa., and Charlottesville, Va. For more information, visit www.rheogene.com.
SOURCE: RHeoGene
Category
License
Standard YouTube License
Why in the world would anyone with consciousness develop such patents?-Looks a lot like warfare to me.I'm counting on you and your answer.
ReplyDeleteKind regards.
I don't know if you will accept an explanation with God or not. If you don;t the reasoning is the same if you take God out of the sentence. I think it is basically comes down to free will. Man was born with or God gave man free will. Good and Evil are real. Our ability to think clearly gets compromised to various degrees throughout life and our will becomes less free. Some are even brainwashed and have little free will left. The choices between good evil are not always clear and we often make bad choices.. Power is a temptation and Accumulating power is addicting to some. Power corrupts and absolute power corrupts absolutely Some people choose evil because they like the power they feel . Some people get sucked into things that end up being evil and some will choose the good, Many areas of life these days tend to be gray and the good is not so easy to distinguish. But I think these kinds of patents and the thinking that leads to them is because some people choose to cooperate with evil.
Delete